Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8655 · 1 trial · 1 indication
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Blood for fasting plasma glucose (central laboratory) was obtained after at least 10 hours overnight fast.
| Arm | Type | Description |
|---|---|---|
| MK-8655 80 mg/MK-8655 320 mg | EXPERIMENTAL | Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days. |
| Placebo | PLACEBO_COMPARATOR | Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days. |
| Name | Type | Description |
|---|---|---|
| MK-8655 | DRUG | Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies. |
| Placebo | DRUG | Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16). |
Inclusion Criteria: * Male or female of non-child bearing potential * Body Mass Index ≤40 kg/m\^2 * Diagnosis of Type 2 Diabetes (T2DM) and is either drug naive or is being treated with metformin only * In good health except for T2DM * Willing to follow a standard diet * Nonsmoker and/or no use of ...
Top 20 of 31 competitors
MK-8655 is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is a metabolic therapeutic that has been studied in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
The molecular target of MK-8655 has not been disclosed. It is a small molecule being studied for its effects on Type 2 Diabetes, but the specific biological target is not publicly available.
MK-8655 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical research on this investigational drug for Type 2 Diabetes.
MK-8655 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received FDA approval and is not yet available as a marketed therapy.
MK-8655 has one completed clinical trial, NCT01640873, which was a Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with Type 2 Diabetes. The trial enrolled 33 participants and was placebo-controlled, randomized, and double-blind.
No alternative names for MK-8655 have been disclosed. It is identified solely by its development code MK-8655 in clinical trial records and by the developer, Merck & Company, Inc.